

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 05 2001

In re the application of:

VERVOORT ET AL.

Serial Number: 09/623,329



Group Art Unit: To be assigned

Filed: August 31, 2000

Examiner: To be assigned

For: OLIGONUCLEOTIDE FOR THE AMPLIFICATION AND DETECTION OF EPSTEIN
BARR VIRUS (EBV) NUCLEIC ACID

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Assistant Commissioner of Patents
Washington, D.C. 20231

November 10, 2000

Sir:

In the Information Disclosure Statement filed August 31, 2000, Applicants reported that copies of three references cited in the PCT Search Report and listed on the form PTO-1449 were not included because they had not yet been provided to the undersigned. Those three references are JP 05 309 0 00 A (line AC); Patent Abstracts of Japan, vol. 18, no. 114, 1994 (line AN); and Brink et al. (line AT).

The three above identified references have now been provided to the undersigned and are submitted herewith.

No fee or certification is required in connection with this Supplemental Information Disclosure Statement since it is being submitted prior to the issuance of a first official action on the merits as well as prior to the expiration of the three month period following filing of the present application.

These references are provided so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

1

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope addressed to: Assistant
Commissioner of Patents, Washington, D.C.
20231 on 11/10/00
Date Of Deposit


William M. Blackstone
Registration No. 29,772

Signature

Date

The Patent Office is authorized to charge our Deposit Account No. 02-2334 for any fee that it deems to be required to effect consideration of this statement.

Respectfully submitted,


William M. Blackstone
Attorney for Applicants
Registration No. 29,772

Attorney Docket No. T/98362 US

Akzo Nobel Patent Department
1300 Piccard Drive, Suite 206
Rockville, Maryland 20850-4373
Tel: (301) 948-7400
Fax: (301) 948-9751
WMB:jlc

NOVERVOORT-SUPP IDS